IBKS No2 SPAC - Asset Resilience Ratio
IBKS No2 SPAC (204840) has an Asset Resilience Ratio of 0.42% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of IBKS No2 SPAC for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how IBKS No2 SPAC's Asset Resilience Ratio has changed over time. See IBKS No2 SPAC free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down IBKS No2 SPAC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of IBKS No2 SPAC.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩206.20 Million | 0.42% |
| Total Liquid Assets | ₩206.20 Million | 0.42% |
Asset Resilience Insights
- Limited Liquidity: IBKS No2 SPAC maintains only 0.42% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
IBKS No2 SPAC Industry Peers by Asset Resilience Ratio
Compare IBKS No2 SPAC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401 |
Drug Manufacturers - Specialty & Generic | 5.09% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Annual Asset Resilience Ratio for IBKS No2 SPAC (2015–2024)
The table below shows the annual Asset Resilience Ratio data for IBKS No2 SPAC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 10.03% | ₩4.26 Billion ≈ $2.89 Million |
₩42.44 Billion ≈ $28.76 Million |
-0.34pp |
| 2023-12-31 | 10.37% | ₩4.14 Billion ≈ $2.80 Million |
₩39.87 Billion ≈ $27.02 Million |
-0.98pp |
| 2022-12-31 | 11.36% | ₩4.64 Billion ≈ $3.14 Million |
₩40.85 Billion ≈ $27.69 Million |
-8.61pp |
| 2021-12-31 | 19.97% | ₩6.37 Billion ≈ $4.32 Million |
₩31.89 Billion ≈ $21.61 Million |
-7.19pp |
| 2020-12-31 | 27.16% | ₩9.49 Billion ≈ $6.43 Million |
₩34.94 Billion ≈ $23.68 Million |
+24.68pp |
| 2019-12-31 | 2.48% | ₩658.41 Million ≈ $446.19K |
₩26.55 Billion ≈ $17.99 Million |
-3.10pp |
| 2018-12-31 | 5.58% | ₩1.76 Billion ≈ $1.19 Million |
₩31.56 Billion ≈ $21.39 Million |
-48.92pp |
| 2017-12-31 | 54.50% | ₩8.19 Billion ≈ $5.55 Million |
₩15.02 Billion ≈ $10.18 Million |
-4.17pp |
| 2016-12-31 | 58.67% | ₩7.25 Billion ≈ $4.91 Million |
₩12.35 Billion ≈ $8.37 Million |
+51.14pp |
| 2015-12-31 | 7.53% | ₩667.27 Million ≈ $452.20K |
₩8.86 Billion ≈ $6.01 Million |
-- |
About IBKS No2 SPAC
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disea… Read more